Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Anavex Provides Update on Blarcamesine, Phase 3 AVATAR Trial Addressing Concerns
February 5th 2022After changes were made to the AVATAR phase 3 study in Rett syndrome, Anavex provided context on the timing of the adjustments, which were approved by regulatory bodies in the UK and Australia, where the trial was conducted.
Challenges in Pediatric Neurocritical Care, Clinician Demographics Identified in Survey
February 4th 2022Most child neurologist respondents were generally early in their career, had diverse subspeciality training, and tended to work at large, resource-rich centers capable of multimodal neuromonitoring.
Blarcamesine Shows Promise as Potential Rett Syndrome Treatment, New Data Indicate
February 2nd 2022Treatment with blarcamesine resulted in statistically significant improvements on the new primary end point and significantly reduced Rett syndrome symptoms through changes in potential biomarkers of disease pathology.
NeuroVoices: Joanna Hellmuth, MD, MS, on COVID-19 Pathogenesis and Long-Term Cognitive Changes
February 2nd 2022The cognitive neurologist at the University of California, San Francisco provided insight on the research needed to explain more about COVID-19’s pathogenesis and the realistic possibility of developing neurocognitive disorders.
NeuroVoices: Joanna Hellmuth, MD, MS, on Recognizing, Characterizing Post-COVID Cognitive Changes
January 26th 2022The cognitive neurologist at the University of California, San Francisco discussed recently published data on the presence of cognitive post-acute sequelae of COVID-19 and the need to legitimize these conditions.
Phase 2 Trial of Sodium Oligomannate in Parkinson Disease Greenlit by FDA
January 25th 2022Approximately 300 patients across 30 clinical centers will be included in the 36-week study evaluating the efficacy and safety of sodium oligomannate (GV-971), a medication currently approved for Alzheimer disease in China.
Phase 2/3 Study of Tau-Targeting Agent E2814 in Alzheimer Disease Enrolls First Patient
January 23rd 2022The trial will also include another investiartional Eisai agent, the antiamyloid therapy lecanemab, as the background study drug to evaluate the true effect of E2814 has on patients with dominantly inherited Alzheimer disease.
Management of Epilepsy More Complicated With Presence of Focal Seizures, Survey Suggests
January 22nd 2022In a Health Union survey of more than 400 patients, those with focal seizures were more likely to say they’ve experienced discrimination, isolation, and reduced productivity at work compared with those without.
Plaque-Inflammation Identified by FDG-PET Associated With Recurrent Ipsilateral Stroke
January 21st 2022The risk of 5-year ipsilateral recurrent stroke was 14.3% for those with Symptomatic Carotid Atheroma Inflammation Lumen-Stenosis scores of at least 3 compared with 2.6% for those with low-risk category scores.
NeuroVoices: Irene Wang, PhD, on the Future of MR Fingerprinting and its Impact on Epilepsy Surgery
January 19th 2022The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided an inside look at the ways MR fingerprinting can provide real-time clinical benefit for physicians and patient care.
Long-Term Maintenance of Regular Physical Activity Slows Parkinson Disease Progression
January 18th 2022Habits of moderate-to-vigorous exercise were preferentially associated with slower decline of postural and gait stability, and work-related activity levels were primarily associated with slower deterioration of processing speed.
Using Tailored Cognitive Behavioral Therapy to Address Psychogenic Nonepileptic Seizures
January 17th 2022Becky Tilahun, PhD, a clinical psychologist at Cleveland Clinic, offered insight into a recent study she and colleagues conducted exploring CBT-informed psychotherapy for patients with psychogenic nonepileptic seizures